The latest price of adagrasib has been announced!

Adagrasib (Adagrasib) is an excellent oral small molecule inhibitor of KRAS G12C, which has demonstrated its unique research and development potential in a wide range of single and combination treatments. In December 2022, Adagraxibu ushered in an important milestone in its development. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the drug as a targeted therapy for adult patients with locally advanced or metastatic NSCLC harboring a KRAS G12C mutation. This means that adagrasib (sold under the brand name KRAZATI) offers a new treatment option for patients who have already received at least one systemic therapy.

For domestic patients, the original drug of adagrasib is not currently on the market in China, and therefore cannot be included in the medical insurance system. This means that if patients want to obtain this drug, they can only purchase it through overseas channels. In the overseas market, the original American version of adagrasib is expensive, with the price of 200mg*180 tablets per box being as high as hundreds of thousands of yuan. Of course, this price is affected by factors such as exchange rates and may fluctuate, but overall, its high price undoubtedly brings a heavy financial burden to patients.

Recently, a generic drug of adagrasib has appeared on the overseas market, bringing new hope to patients. This generic drug is produced by Lucius Pharmaceutical Factory in Laos. Its ingredients are basically the same as the original drug, but the price is much cheaper. The specification is 200mg*90 tablets, and the price per box is only more than 4,000 yuan. Although the price may fluctuate due to factors such as exchange rates, its price advantage is already quite obvious compared to the original drug.